Natriuretic Peptide's Headache Inducing Characteristics and Effects on the Cerebral Blood Flow

N/ACompletedNCT01637662

Danish Headache Center6 enrolled

Overview

To investigate headache score and accompanying symptoms during and after infusion of the natriuretic peptides.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

SCREENING

Masking

NONE

Enrollment

Conditions

Headache Migraine

Interventions

Natriuretic peptidesDRUG

I.V. infusion between 0.2-3 microgram over 20 minutes

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy volunteers * Aged 18-40 * 50-100 kg * Fertile women must use safe contraceptives (IUD, oral contraceptives, surgical sterilisation and long lasting gestagen. Exclusion Criteria: * Tension type headache more than once/month * Other primary headaches * Daily medication except contraceptives * Drug taken within 4 times the halflife for the specific drug except contraceptives * Pregnant or lactating women * Exposure to radiation within the last year * Headache within the last 24 hours before start of trial * Hypertension * Hypotension * Respiratory or cardiac disease

Locations (1)

Danish Headache Center

Copenhagen, Glostrup, Denmark

Outcomes

Primary Outcomes

Headache intensity, mean velocity of blood flow in the middle cerebral artery (VmeanMCA), superfical temporal artery diameter, PetCO2, adverse events and vital signs were recorded at T-10, T0 and then every 10 min until 120 min after start of infusion.

Time frame: Every 10 min.

Secondary Outcomes

All subjects were asked to complete a headache diary every hour until 10 h after the discharge. The diary included headache characteristics and accompanying symptoms according to the International Headache Society (IHS 2004)

Time frame: 10 hours after discharge

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.